Olive AI: from a $4B healthcare-automation unicorn to a wind-down in two years
Olive sold AI automation for hospital back-office work. It raised hundreds of millions during the 2020–2021 boom and reached a reported $4 billion valuation, then laid off staff, sold its units for small sums and wound down in October 2023.
- Product
- Olive AI
- Founder
- Sean Lane (CEO)
- Launched
- n/a
- Model
- Enterprise software for hospitals
Published · 2 min read · 3 sources
Key takeaways
- Olive raised $225M at a $1.5B valuation in December 2020 and $400M at a reported $4B valuation seven months later.
- In July 2022 it laid off 450 employees; CEO Sean Lane wrote that 'fast-paced growth and lack of focus' strained the company.
- In October 2023 it sold its core units to Waystar ($10M) and Humata Health ($1.25M), as reported by Business First, and wound down.
What it is
Olive used AI to take on "high-volume, repetitive and manual tasks healthcare workers do every day", such as prior authorization (Fierce Healthcare). In 2021 its executives said it was in place at more than 900 hospitals in over 40 US states (Fierce Healthcare).
Timeline
- 2017: CEO Sean Lane and his team first deploy Olive (Fierce Healthcare).
- December 2020: Olive raises $225 million at a $1.5 billion valuation (Fierce Healthcare).
- July 2021: A $400 million round takes its valuation to a reported $4 billion (Fierce Healthcare).
- July 2022: Olive lays off 450 employees, citing the economy and "missteps" in its strategy (Fierce Healthcare).
- April 2023: Availity buys Olive's utilization management product for payers (Fierce Healthcare), for nearly $35 million according to Business First (Becker's Hospital Review).
- 31 October 2023: Olive sells its clearinghouse and patient access units to Waystar and its prior authorization unit to Humata Health, and winds down (Fierce Healthcare). Business First reported prices of $10 million and $1.25 million (Becker's Hospital Review).
Why it worked
- Timing. Olive rose with the digital health funding boom and the need for automation during the pandemic (Fierce Healthcare).
- A clear, boring, expensive problem. Hospital admin work like prior authorization is repetitive and manual, which is exactly what Olive automated (Fierce Healthcare).
What to learn
- Focus beats breadth. Lane wrote: "Our fast-paced growth and lack of focus strained our product and engineering resources and prevented us from executing quickly on key initiatives. I take responsibility for this" (Fierce Healthcare).
- Big rounds raise the bar you must clear. Rock Health linked the closure to "bloated operations and cash constraints" after 2021 (Rock Health).
- A large customer count is not the same as a healthy business: 900+ hospitals in 2021 did not prevent the wind-down two years later (Fierce Healthcare).
Risks and what didn't work
- Spread too thin. Rock Health said operational challenges from being "stretched thin across multiple focus areas led to client losses" (Rock Health).
- Sold for a fraction of its peak. Units went for $10 million and $1.25 million, compared with a reported $4 billion valuation (Becker's Hospital Review).
- Funding totals differ by source. Fierce reports $902 million raised in total, while Becker's says more than $850 million (Fierce Healthcare; Becker's Hospital Review).
- Legal tail. JobsOhio sued the buyers to recover $598,000 in incentives after Olive missed hiring targets (Becker's Hospital Review).
FAQ
Short answers drawn from the sections above.
What is Olive AI?
Olive used AI to take on "high-volume, repetitive and manual tasks healthcare workers do every day", such as prior authorization (Fierce Healthcare). In 2021 its executives said it was in place at more than 900 hospitals in over 40 US states (Fierce Healthcare).
Why did Olive AI work?
- Timing. Olive rose with the digital health funding boom and the need for automation during the pandemic (Fierce Healthcare).
- A clear, boring, expensive problem. Hospital admin work like prior authorization is repetitive and manual, which is exactly what Olive automated (Fierce Healthcare).
What can indie builders learn from Olive AI?
- Focus beats breadth. Lane wrote: "Our fast-paced growth and lack of focus strained our product and engineering resources and prevented us from executing quickly on key initiatives. I take responsibility for this" (Fierce Healthcare).
- Big rounds raise the bar you must clear. Rock Health linked the closure to "bloated operations and cash constraints" after 2021 (Rock Health).
- A large customer count is not the same as a healthy business: 900+ hospitals in 2021 did not prevent the wind-down two years later (Fierce Healthcare).
What didn't work for Olive AI, and what are the risks?
- Spread too thin. Rock Health said operational challenges from being "stretched thin across multiple focus areas led to client losses" (Rock Health).
- Sold for a fraction of its peak. Units went for $10 million and $1.25 million, compared with a reported $4 billion valuation (Becker's Hospital Review).
- Funding totals differ by source. Fierce reports $902 million raised in total, while Becker's says more than $850 million (Fierce Healthcare; Becker's Hospital Review).
- Legal tail. JobsOhio sued the buyers to recover $598,000 in incentives after Olive missed hiring targets (Becker's Hospital Review).
Sources
Every link cited above, in order of first use.
- 1.Fierce Healthcare (fiercehealthcare.com)
- 2.Becker's Hospital Review (beckershospitalreview.com)
- 3.Rock Health (rockhealth.com)
Related case studies
More in AI tools →Forward: $657M raised, an AI 'doctor in a box', and an abrupt shutdown a year later
Forward started as a tech-heavy, cash-pay primary care clinic, then bet on CarePods: self-serve AI kiosks for blood draws and tests without a doctor in the room. A year after launching them, it shut down overnight.
Adept: $400M+ agent startup whose founders left for Amazon
Adept raised over $415M to build AI agents that use software. In June 2024 its cofounders joined Amazon's AGI org and licensed tech to Amazon; investors were later made roughly whole.
Tome: 20 million users of an AI slides app, then a pivot away from slides
Tome rode the ChatGPT wave with an AI presentation tool and tens of millions of mostly free users. It cut staff, moved to sales teams, dropped slides; its founders then launched the AI CRM Lightfield.